NASDAQ:SNDX - Syndax Pharmaceuticals Stock Price, Forecast & News

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) released its earnings results on Thursday, November, 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.48) by $0.07. The company earned $0.38 million during the quarter, compared to analyst estimates of $0.38 million. Syndax Pharmaceuticals had a negative net margin of 4,013.45% and a negative return on equity of 110.20%. View Syndax Pharmaceuticals' Earnings History.

Syndax Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Syndax Pharmaceuticals.

7 equities research analysts have issued twelve-month target prices for Syndax Pharmaceuticals' stock. Their forecasts range from $5.00 to $19.00. On average, they anticipate Syndax Pharmaceuticals' share price to reach $13.80 in the next twelve months. This suggests a possible upside of 57.4% from the stock's current price. View Analyst Price Targets for Syndax Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syndax Pharmaceuticals.

Media coverage about SNDX stock has been trending negative recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Syndax Pharmaceuticals earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Syndax Pharmaceuticals.

Syndax Pharmaceuticals saw a decline in short interest in the month of November. As of November 29th, there was short interest totalling 528,700 shares, a decline of 18.3% from the November 14th total of 647,000 shares. Based on an average trading volume of 152,100 shares, the days-to-cover ratio is presently 3.5 days. Currently, 2.8% of the shares of the stock are sold short. View Syndax Pharmaceuticals' Current Options Chain.

Some companies that are related to Syndax Pharmaceuticals include Odonate Therapeutics (ODT), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH), TG Therapeutics (TGTX), Vanda Pharmaceuticals (VNDA), ZIOPHARM Oncology (ZIOP), Achillion Pharmaceuticals (ACHN), G1 Therapeutics (GTHX), IGM Biosciences (IGMS), Eagle Pharmaceuticals (EGRX), Dova Pharmaceuticals (DOVA), XBiotech (XBIT), Homology Medicines (FIXX), Flexion Therapeutics (FLXN) and CannTrust (CNTTF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include Opko Health (OPK), Exelixis (EXEL), TherapeuticsMD (TXMD), Idera Pharmaceuticals (IDRA), Verastem (VSTM), Cara Therapeutics (CARA), Proteostasis Therapeutics (PTI), Clearside Biomedical (CLSD), Micron Technology (MU) and Progenics Pharmaceuticals (PGNX).

(SNDX) raised $66 million in an IPO on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Syndax Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (1.53%), Bluefin Trading LLC (0.08%), Barclays PLC (0.06%) and Ibex Investors LLC (0.05%). Company insiders that own Syndax Pharmaceuticals stock include Briggs Morrison, Michael L Meyers and Peter Ordentlich. View Institutional Ownership Trends for Syndax Pharmaceuticals.

SNDX stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. View Insider Buying and Selling for Syndax Pharmaceuticals.

SNDX stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Bluefin Trading LLC and Ibex Investors LLC. Company insiders that have bought Syndax Pharmaceuticals stock in the last two years include Briggs Morrison and Michael L Meyers. View Insider Buying and Selling for Syndax Pharmaceuticals.

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SNDX stock can currently be purchased for approximately $8.77.

Syndax Pharmaceuticals has a market capitalization of $238.02 million and generates $1.52 million in revenue each year. The company earns $-73,960,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Syndax Pharmaceuticals employs 38 workers across the globe.View Additional Information About Syndax Pharmaceuticals.

The official website for Syndax Pharmaceuticals is http://www.syndax.com/.

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]